

**North America Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher's Disease, MPS-1 & IV, Cancer, Alzheimer's Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]**

Market Report | 2022-11-18 | 193 pages | The Insight Partners

**AVAILABLE LICENSES:**

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

**Report description:**

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

The glycomic therapeutics market in North America is expected to grow from US\$ 42.55 billion in 2022 to US\$ 100.79 billion by 2028; it is estimated to grow at a CAGR of 15.5% from 2022 to 2028.

#### Application in Treatment of Broad Range of Disorders Drives Market Growth

Glycan-based products have wide applications in the therapeutic industry; the products are available in different structures & forms and developed as per the application. This drug is designed for various diseases, such as thrombosis, anaemia, cancer, influenza, cataract, and anti-inflammation. The glycoprotein is a type of glycan that can be used to deliver drugs, toxins, or radioactive substances directly to cancer cells. Monoclonal antibodies, including erythropoietin (EPO) and Herceptin (trastuzumab), are widely used and are a part of several research projects. These products are aimed at expanding and improving their applicability and efficacy. EPO has been used to treat traumatic brain injury (TBI) in young patients and Alzheimer's disease in rodent models due to its known neuroprotective effects. The largest and fastest-growing application category is drug discovery and development, mostly due to the rise in R&D by pharmaceutical and biotechnology firms and the expansion of drug discovery research activities in university research institutions.

For instance, in April 2020, researchers from the Institute for Glycomics and the University of Adelaide signed an exclusive licensing agreement with Sienna Cancer Diagnostics Ltd. to commercialize a cutting-edge cancer detection tool. The researchers have created SubB2M, a special protein that attaches itself exclusively to a sugar molecule, only found in cancer cells. The researchers have claimed that the protein might revolutionize cancer detection.

In March 2021, 48Hour Discovery (48HD) and CQDM announced that the firms received an award of US\$ 800,000 for peptide drug development utilizing its unique drug discovery platform. The CQDM Quantum Leap initiative, which encourages research into cutting-edge technologies, methods, and platforms that speed up or expedite drug discovery and development, provided funding for the two-year study. Merck, a CQDM member, is financing the study. The University of Alberta and 48HD will work together on the project. Additionally, GlycoNet, a Network of Centres of Excellence centered at the University of Alberta for Glycomics Research, is providing the funds to enhance the quality of life of Canadians.

In March 2022, researchers from the Canadian Glycomics Network (GlycoNet) developed a novel combination medication for Sanfilippo syndrome, which is showing encouraging preclinical outcomes. Researchers at Kaleido Biosciences are developing therapeutics for immune-mediated and inflammatory diseases with synthetic glycans that are selectively metabolized in the gut microbiome to suppress the growth of bacteria associated with inflammation. One synthetic glycan candidate, KB295, is intended to treat ulcerative colitis, an inflammatory bowel disorder (IBD). The administration of microbiome-mediating glycans could radically improve treatment by 16% of IBD sufferers who do not respond to the current standard of care and other patients with hard-to-treat autoimmune and inflammatory conditions. These advancements show that glycomics has the potential to provide rapid and accurate therapeutic results for complex conditions. Therefore, the use of glycomics in drug development for diseases across the region drives the glycomics therapeutics market.

#### Market Overview

The North America glycomic therapeutics market is segmented into the US, Canada, and Mexico. The US held the largest share of the North America glycomic therapeutics market in 2022. The increasing demand in the region, followed by rising research and development activities by various major firms, rising number of investments in glycomic therapeutics research, and growing awareness about glycomic therapeutics, is expected to drive the overall glycomic therapeutics market during the forecast period.

#### North America Glycomic Therapeutics Market Revenue and Forecast to 2028 (US\$ Billion)

#### North America Glycomic Therapeutics Market Segmentation

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The North America glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.

Based on class, the North America glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022. Based on structure, the North America glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022. Based on indications, the North America glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher's disease, MPS-1 & IV, cancer, alzheimer's disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022. Based on mode of action, the North America glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the North America glycomic therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022. BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Halozyme Therapeutics, Inc.; Bayer AG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Lt. are the leading companies operating in the glycomic therapeutics in North America.

## **Table of Contents:**

### TABLE OF CONTENTS

1. Introduction
  - 1.1 Study Scope
  - 1.2 The Insight Partners Research Report Guidance
  - 1.3 Market Segmentation
    - 1.3.1 North America Glycomic Therapeutics Market - By Class
    - 1.3.2 North America Glycomic Therapeutics Market - By Structures
    - 1.3.3 North America Glycomic Therapeutics Market - By Indications
    - 1.3.4 North America Glycomic Therapeutics Market - By Mode of Action
    - 1.3.5 North America Glycomic Therapeutics Market - By Country
2. North America Glycomic Therapeutics Market- Key Takeaways
3. Research Methodology
  - 3.1 Coverage
  - 3.2 Secondary Research
  - 3.3 Primary Research
4. North America Glycomic Therapeutics Market Landscape
  - 4.1 Overview
  - 4.2 North America PEST Analysis
  - 4.3 Expert Opinion
5. North America Glycomic Therapeutics Market - Key Market Dynamics
  - 5.1 Market Drivers
    - 5.1.1 Wide Application in Various Disorders Followed by the Development of New Treatment Processes
    - 5.1.2 Increasing Research and Development In the Field of Glycomic Therapeutics
  - 5.2 Market Restraints
    - 5.2.1 Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 5.3 Market Opportunities
  - 5.3.1 Wide Applications of Glycomics in Therapeutics
- 5.4 Future Trends
  - 5.4.1 New Tools in Glycomics Research
- 5.5 Impact Analysis
- 6. Glycomic Therapeutics Market- North America Analysis
  - 6.1 North America Glycomic Therapeutics Market Revenue Forecast and Analysis
    - 6.1.1 North America: Glycomic Therapeutics Market, 2019-2028 (US\$ Million)
- 7. North America Glycomic Therapeutics Market Revenue and Forecast to 2028- by Class
  - 7.1 Overview
  - 7.2 North America Glycomic Therapeutics Market, By Class 2022 & 2028 (%)
    - 7.2.1 North America: Glycomic Therapeutics Market, by Class, 2019-2028 (US\$ Million)
  - 7.3 Isolated
    - 7.3.1 Overview
    - 7.3.2 North America Isolated Revenue and Forecast to 2028 (US\$ Million)
  - 7.4 Synthetic
    - 7.4.1 Overview
    - 7.4.2 North America Synthetic - Revenue and Forecast to 2028 (US\$ Million)
- 8. North America Glycomics Therapeutics Market Analysis and Forecasts To 2028 - By Indication
  - 8.1 Overview
  - 8.2 North America Glycomics Market, By Indication 2022 & 2028 (%)
    - 8.2.1 North America: Glycomic Therapeutics Market, by Indication, 2019-2028 (US\$ Million)
  - 8.3 Thrombosis and Chemoprophylaxis
    - 8.3.1 Overview
    - 8.3.2 North America Thrombosis and chemoprophylaxis Revenue and Forecast to 2028 (US\$ Million)
  - 8.4 Anaemia
    - 8.4.1 Overview
    - 8.4.2 North America Anaemia Revenue and Forecast to 2028 (US\$ Million)
  - 8.5 Anti-adhesive and Anti-inflammatory
    - 8.5.1 Overview
    - 8.5.2 North America Anti-adhesive and Anti-inflammatory Revenue and Forecast to 2028 (US\$ Million)
  - 8.6 Cataract
    - 8.6.1 Overview
    - 8.6.2 North America Cataract Revenue and Forecast to 2028 (US\$ Million)
  - 8.7 Gaucher's diseases
    - 8.7.1 Overview
    - 8.7.2 North America Gaucher's diseases Revenue and Forecast to 2028 (US\$ Million)
  - 8.8 MPS-1 & IV
    - 8.8.1 Overview
    - 8.8.2 North America MPS-1 & IV Revenue and Forecast to 2028 (US\$ Million)
  - 8.9 Cancer
    - 8.9.1 Overview
    - 8.9.2 North America Cancer Revenue and Forecast to 2028 (US\$ Million)
  - 8.10 Alzheimer's
    - 8.10.1 Overview
    - 8.10.2 North America Alzheimer's Revenue and Forecast to 2028 (US\$ Million)
  - 8.11 Influenza Type A and B

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.11.1 Overview
- 8.11.2 North America Influenza Type A and B Revenue and Forecast to 2028 (US\$ Million)
- 8.12 Others
  - 8.12.1 Overview
  - 8.12.2 North America Others Revenue and Forecast to 2028 (US\$ Million)
- 9. North America Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Structures
  - 9.1 Overview
  - 9.2 North America Glycomic Therapeutics Market, By Structures 2022 & 2028 (%)
    - 9.2.1 North America: Glycomic Therapeutics Market, by Structure, 2019-2028 (US\$ Million)
      - 9.2.1.1 North America: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US\$ Million)
      - 9.2.1.2 North America: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US\$ Million)
      - 9.2.1.3 North America: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US\$ Million)
      - 9.2.1.4 North America: Glycomic Therapeutics Market, by Others, 2019-2028 (US\$ Million)
  - 9.3 Glycoproteins
    - 9.3.1 Overview
    - 9.3.2 North America Glycoproteins - Market Revenue and Forecast to 2028 (US\$ Million)
  - 9.4 Targeting Sialic Acid
    - 9.4.1 Overview
    - 9.4.2 North America Targeting Sialic Acid - Market Revenue and Forecast to 2028 (US\$ Million)
    - 9.4.3 Zanamivir
      - 9.4.3.1 Overview
      - 9.4.3.2 North America Zanamivir - Market Revenue and Forecast to 2028 (US\$ Million)
    - 9.4.4 Oseltamivir
      - 9.4.4.1 Overview
      - 9.4.4.2 North America Oseltamivir - Market Revenue and Forecast to 2028 (US\$ Million)
  - 9.5 Proteoglycans
    - 9.5.1 Overview
    - 9.5.2 North America Proteoglycans - Market Revenue and Forecast to 2028 (US\$ Million)
  - 9.6 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans
    - 9.6.1 Overview
    - 9.6.2 North America Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecast to 2028 (US\$ Million)
  - 9.7 Targeting Glycosaminoglycans
    - 9.7.1 Overview
    - 9.7.2 North America Targeting Glycosaminoglycans - Market Revenue and Forecast to 2028 (US\$ Million)
    - 9.7.3 Heparin
      - 9.7.3.1 Overview
      - 9.7.3.2 North America Heparin - Market Revenue and Forecast to 2028 (US\$ Million)
    - 9.7.4 Hyaluronan (HA)
      - 9.7.4.1 Overview
      - 9.7.4.2 North America Hyaluronan (HA)- Market Revenue and Forecast to 2028 (US\$ Million)
    - 9.7.5 Laronidase
      - 9.7.5.1 Overview
      - 9.7.5.2 North America Laronidase - Market Revenue and Forecast to 2028 (US\$ Million)
    - 9.7.6 Galsulfase (Naglazyme)
      - 9.7.6.1 Overview
      - 9.7.6.2 North America Galsulfase (Naglazyme) - Market Revenue and Forecast to 2028 (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.7.7 Hyaluronidase (Cumulase)
  - 9.7.7.1 Overview
  - 9.7.7.2 North America Hyaluronidase (Cumulase) - Market Revenue and Forecast to 2028 (US\$ Million)
- 9.7.8 Others
  - 9.7.8.1 Overview
  - 9.7.8.2 North America Others - Market Revenue and Forecast to 2028 (US\$ Million)
- 9.8 Targeting Glycosphingolipids
  - 9.8.1 Overview
  - 9.8.2 North America Targeting Glycosphingolipids - Market Revenue and Forecast to 2028 (US\$ Million)
  - 9.8.3 Imiglucerase (Cerezyme)
    - 9.8.3.1 Overview
    - 9.8.3.2 North America Imiglucerase (Cerezyme)- Market Revenue and Forecast to 2028 (US\$ Million)
    - 9.8.3.3 Agalsidase (Fabrazyme)
      - 9.8.3.3.1 Overview
      - 9.8.3.3.2 North America Agalsidase (Fabrazyme) - Market Revenue and Forecast to 2028 (US\$ Million)
    - 9.8.3.4 N-butyl-deoxynojirimycin (DNJ)
      - 9.8.3.4.1 Overview
      - 9.8.3.4.2 North America N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecast to 2028 (US\$ Million)
  - 9.8.4 Others
    - 9.8.4.1 Overview
    - 9.8.4.2 North America Others - Market Revenue and Forecast to 2028 (US\$ Million)
- 9.9 Others
  - 9.9.1 Overview
  - 9.9.2 North America Others - Market Revenue and Forecast to 2028 (US\$ Million)
  - 9.9.3 Acarbose
    - 9.9.3.1 Overview
    - 9.9.3.2 North America Acarbose - Market Revenue and Forecast to 2028 (US\$ Million)
    - 9.9.3.3 Alglucosidase Alfa (Myozyme)
      - 9.9.3.3.1 Overview
      - 9.9.3.3.2 North America Alglucosidase Alfa (Myozyme) - Market Revenue and Forecast to 2028 (US\$ Million)
    - 9.9.3.4 Allosamidin
      - 9.9.3.4.1 Overview
      - 9.9.3.4.2 North America Allosamidin - Market Revenue and Forecast to 2028 (US\$ Million)
  - 9.9.4 Others
    - 9.9.4.1 Overview
    - 9.9.4.2 North America Others - Market Revenue and Forecast to 2028 (US\$ Million)
- 10. North America Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Mode of Action
  - 10.1 Overview
  - 10.2 North America Glycomic Therapeutics Market, By Mode of Action 2022 & 2028 (%)
    - 10.2.1 North America: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US\$ Million)
  - 10.3 Inhibits Neuraminidase
    - 10.3.1 Overview
    - 10.3.2 North America Inhibits Neuraminidase - Market Revenue and Forecast to 2028 (US\$ Million)
  - 10.4 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate
    - 10.4.1 Overview
    - 10.4.2 North America Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecast to 2028 (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## 10.5 Erythropoietin And Enzyme Replacement Therapy (ERT)

### 10.5.1 Overview

### 10.5.2 North America Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecast to 2028 (US\$ Million)

## 10.6 Tissue Plasminogen Activator

### 10.6.1 Overview

### 10.6.2 North America Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US\$ Million)

## 10.7 Inhibits Glucosylceramide Synthase

### 10.7.1 Overview

### 10.7.2 North America Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US\$ Million)

## 10.8 Interleukin 1 And 2 And 3

### 10.8.1 Overview

### 10.8.2 North America Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US\$ Million)

## 10.9 Beta And Gamma Interferons

### 10.9.1 Overview

### 10.9.2 North America Beta And Gamma Interferons- Market Revenue And Forecasts To 2028 (US\$ Million)

## 10.10 Others

### 10.10.1 Overview

### 10.10.2 North America Others- Market Revenue And Forecasts To 2028 (US\$ Million)

## 11. North America Glycomic Therapeutics Market Revenue and Forecasts to 2028 - Country Analysis

### 11.1 North America: Glycomic Therapeutics Market

#### 11.1.1 Overview

#### 11.1.2 North America: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)

#### 11.1.3 US: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US\$ Million)

##### 11.1.3.1.1 Overview

##### 11.1.3.1.2 US: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US\$ Million)

##### 11.1.3.1.3 US: Glycomic Therapeutics Market, by Class, 2019-2028 (US\$ Million)

##### 11.1.3.1.4 US: Glycomic Therapeutics Market, by Structure, 2019-2028 (US\$ Million)

##### 11.1.3.1.4.1 US: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US\$ Million)

##### 11.1.3.1.4.2 US: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US\$ Million)

##### 11.1.3.1.4.3 US: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US\$ Million)

##### 11.1.3.1.4.4 US: Glycomic Therapeutics Market, by Others, 2019-2028 (US\$ Million)

##### 11.1.3.1.5 US: Glycomic Therapeutics Market, by Indication, 2019-2028 (US\$ Million)

##### 11.1.3.1.6 US: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US\$ Million)

#### 11.1.3.2 Canada: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US\$ Million)

##### 11.1.3.2.1 Overview

##### 11.1.3.2.2 Canada: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US\$ Million)

##### 11.1.3.2.3 Canada: Glycomic Therapeutics Market, by Class, 2019-2028 (US\$ Million)

##### 11.1.3.2.4 Canada: Glycomic Therapeutics Market, by Structure, 2019-2028 (US\$ Million)

##### 11.1.3.2.4.1 Canada: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US\$ Million)

##### 11.1.3.2.4.2 Canada: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US\$ Million)

##### 11.1.3.2.4.3 Canada: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US\$ Million)

##### 11.1.3.2.4.4 Canada: Glycomic Therapeutics Market, by Others, 2019-2028 (US\$ Million)

##### 11.1.3.2.5 Canada: Glycomic Therapeutics Market, by Indication, 2019-2028 (US\$ Million)

##### 11.1.3.2.6 Canada: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US\$ Million)

#### 11.1.3.3 Mexico: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US\$ Million)

##### 11.1.3.3.1 Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.1.3.3.2 Mexico: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.1.3.3.3 Mexico: Glycomic Therapeutics Market, by Class, 2019-2028 (US\$ Million)
- 11.1.3.3.4 Mexico: Glycomic Therapeutics Market, by Structure, 2019-2028 (US\$ Million)
- 11.1.3.3.4.1 Mexico: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US\$ Million)
- 11.1.3.3.4.2 Mexico: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US\$ Million)
- 11.1.3.3.4.3 Mexico: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US\$ Million)
- 11.1.3.3.4.4 Mexico: Glycomic Therapeutics Market, by Others, 2019-2028 (US\$ Million)
- 11.1.3.3.5 Mexico: Glycomic Therapeutics Market, by Indication, 2019-2028 (US\$ Million)
- 11.1.3.3.6 Mexico: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US\$ Million)
- 12. Glycomic Therapeutics Market -Industry Landscape
- 12.1 Overview
- 12.2 Growth Strategies in the Glycomic Therapeutics Market (%)
- 12.3 Organic Developments
- 12.3.1 Overview
- 12.4 Inorganic Developments
- 12.4.1 Overview
- 13. Company Profiles
- 13.1 BioMarin Pharmaceutical Inc.
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
- 13.2 Genzyme Corporation (Sanofi)
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
- 13.3 Halozyme Therapeutics, Inc.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 Bayer AG
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
- 13.5 Alzheon, Inc.
- 13.5.1 Key Facts

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
- 13.6 GlaxoSmithKline plc.
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
- 13.7 F. Hoffmann-La Roche Ltd
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 14. Appendix
- 14.1 About The Insight Partners
- 14.2 Glossary of Terms in Glycomic Therapeutics Market

**North America Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher's Disease, MPS-1 & IV, Cancer, Alzheimer's Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]**

Market Report | 2022-11-18 | 193 pages | The Insight Partners

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to [support@scotts-international.com](mailto:support@scotts-international.com)


**ORDER FORM:**

Select license	License	Price
----------------	---------	-------

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



Single User Price
-------------------

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)






Site Price
------------












**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)





**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)


**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)







**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.  
☐\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-07"/>
		Signature	<div><div></div></div>